Literature DB >> 7591234

No preferential loss of one parental allele of chromosome 17p13.3 in childhood medulloblastoma.

W G Scheurlen1, J Krauss, J Kühl.   

Abstract

Medulloblastomas are the most frequent malignant tumors of the central nervous system in childhood. Loss of heterozygosity of the telomeric part of chromosome 17p has been described frequently in these tumors, suggesting a possible second tumor-suppressor gene in this region apart from the p53 gene. Using restriction-fragment-length polymorphism and microsatellite polymorphism analysis, we screened 16 medulloblastomas for 17p13.3 deletions and compared the DNA patterns of patients' tumors and normal tissues with those of one or both parents. Loss of heterozygosity of chromosome 17p13.3 could be detected in 6 out of 16 tumors (37.5%). In 4 of these 6 tumors the maternal allele was deleted, in 2 tumors the paternal allele. Although the number of tumors investigated is limited, we find no evidence that genomic imprinting of the chromosomal region most frequently deleted in medulloblastoma plays a role in tumorigenesis.

Entities:  

Mesh:

Year:  1995        PMID: 7591234     DOI: 10.1002/ijc.2910630312

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Molecular analysis of medulloblastomas occurring simultaneously in monozygotic twins.

Authors:  W Scheurlen; N Sörensen; W Roggendorf; J Kühl
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

2.  Cytogenetic and histopathologic studies of congenital supratentorial primitive neuroectodermal tumors: a case report.

Authors:  H J Girschick; R Klein; W G Scheurlen; J Kühl
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Loss of heterozygosity analysis of chromosome 17p13.1-13.3 and its correlation with clinical outcome in medulloblastomas.

Authors:  Hye Lim Jung; Kyu-Chang Wang; Seung-Ki Kim; Ki Woong Sung; Hong Hoe Koo; Hee Young Shin; Hyo Seop Ahn; Hyung Jin Shin; Byung-Kyu Cho
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.